Zimmer Biomet raised its 2026 outlook: Organic sales growth is now expected at 2.25% to 3.25%, and adjusted EPS guidance increased to $8.47-$8.59. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Zimmer Biomet raised adjusted EPS guidance to $8.47 to $8.59, from $8.40 to $8.55. About Zimmer Biomet (NYSE:ZBH)Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The article "Zimmer Biomet Q2 Earnings Call Highlights" was originally published by MarketBeat.